Research Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Liver Diseases
ClinicalTrials.gov# 
NCT03053063
Status 
Recruiting
Study Start/End 
Sep 7, 2017 to Oct 31, 2023
Locations 
Diamond Health Care Centre
Name/Title 
Jo-Ann Ford, Clinical Research Coordinator
Phone 
604-875-5705
Email Address 
jo-ann.ford@vch.ca
Purpose of Study 

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.